Diabetes & Metabolism

Diabetes mellitus and hypertension are two of the most common diseases in Westernized, industrialized civilizations, and the frequency of both diseases increases with increasing age. Diabetes mellitus is characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action or both, and associated with a considerably increased cardiovascular risk, peripheral vascular diseases, stroke, retinopathy, and nephropathy. Two types of diabetes mellitus are recognized based on the presumed etiology. In type 1 diabetes, the body fails to produce insulin as a result of an auto-immune reaction that destroys the islet cells in the pancreas that produce insulin, and daily insulin injections are required. Type 1 diabetes is usually diagnosed during childhood or early adolescence and it affects about 1 in every 600 children. Type 2 diabetes is the result of failure to produce sufficient insulin and insulin resistance. Elevated blood glucose levels are managed with reduced food intake, increased physical activity, and eventually oral medications or insulin. Type 2 diabetes is typically diagnosed during adulthood. However with the increasing incidence of childhood obesity and concurrent insulin resistance, the number of children diagnosed with type 2 diabetes has also increased worldwide.
The hallmark of hypertension in type I and type II diabetics appears to be increased peripheral vascular resistance. Increased exchangeable sodium may also play a role in the pathogenesis of blood pressure in diabetics. Evidence is accumulating that insulin resistance, or hyperinsulinemia, may play a key role in the pathogenesis of hypertension in both subtle and overt abnormalities of carbohydrate metabolism. Population studies suggest that elevated insulin levels, which often occurs in type II diabetes mellitus, is an independent risk factor for cardiovascular disease. Other cardiovascular risk factors in diabetic individuals include abnormalities of lipid metabolism, platelet function, and clotting factors.

22 Item(s)

per page
Axon ID Name Description From price
2340 AZ-GHS-22 Orally available Ghrelin receptor (GHS-R1a) inverse agonist €160.00
2147 CpdD hydrochloride Ghrelin receptor (GhrR aka GHSR-1a) antagonist €135.00
2727 Elafibranor Dual PPARα/δ agonist €90.00
2686 FH535 Dual inhibitor of PPAR and Wnt/β-catenin signaling €75.00
2706 FH535 sodium salt Dual inhibitor of PPAR and Wnt/β-catenin signaling €80.00
2363 GSK 2033 The first potent cell-active LXR antagonist €105.00
1628 GSK 3787 PPARδ antagonist €90.00
1266 GW 3965 hydrochloride Liver X receptor agonist €95.00
2262 GW 9662 Selective PPARγ antagonist €60.00
2019 INT131 Selective PPARγ modulator (partial agonist) €90.00
1567 KRP 297 PPARα agonist; PPARγ agonist €110.00
2357 LXR 623 Partial agonist of Liver X Receptor €95.00
2814 MHY 553 PPARα agonist €95.00
2402 MHY 908 Dual PPARα/γ agonist, and potent inhibitor of mushroom tyrosinase €95.00
1376 MK 677 Growth hormone secretagogue (GHS) agonist €80.00
3739 RGX-104 Liver X receptor (LXR) agonist Inquire
3999 Saroglitazar magnesium Potent dual PPARα/γ agonist €160.00
2807 SPA70 Potent and selective human pregnane X receptor (hPXR) antagonist €125.00
2598 SR 9243 LXR inverse agonist inhibiting the Warburg effect and lipogenesis in cancer cells €85.00
2754 T0901317 Liver X receptor (LXR) agonist €75.00
3486 TM-N1324 Highly potent and selective GPR39 agonist €110.00
1991 WYE 672 Liver X receptor (LXR) agonist €120.00

22 Item(s)

per page
Please wait...